Pure US Cannabis ETF Jumps 8% on June 29 DEA Rescheduling Hearing
MSOS•The Pure US Cannabis ETF surged over 8% Friday as investors bet on the DEA scheduling hearing set for June 29 and legislative efforts to preserve hemp-derived CBD legality beyond June. Year-to-date MSOS has climbed 8% despite underperforming the S&P 500, reflecting heightened sector optimism.
1. ETF Performance Surge
MSOS soared more than 8% on Friday as a wave of buying swept through the cannabis ETF following positive regulatory signals. The ETF’s volume spiked as investors rotated into sector exposure ahead of the federal rescheduling hearing.
2. Regulatory Developments
Investors are eyeing the June 29 DEA hearing to potentially move marijuana from Schedule I to Schedule III, which would broaden commercial and medical access. Concurrently, federal proposals to amend hemp regulations aim to preserve full-spectrum CBD product legality beyond June’s pending ban.
3. Year-to-Date Performance
Since the start of the year, MSOS has climbed just over 8% compared with a higher return on the S&P 500, reflecting both sector-specific volatility and broader market trends. This underperformance underscores the cannabis sector’s sensitivity to policy developments and investor sentiment shifts.
